We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Alnylam Research on miRNAs Featured in The New England Journal of Medicine
News

Alnylam Research on miRNAs Featured in The New England Journal of Medicine

Alnylam Research on miRNAs Featured in The New England Journal of Medicine
News

Alnylam Research on miRNAs Featured in The New England Journal of Medicine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alnylam Research on miRNAs Featured in The New England Journal of Medicine "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Alnylam Pharmaceuticals, Inc. has announced that its research on therapeutic silencing of microRNAs was featured in an article published in the March 16, 2006 issue of The New England Journal of Medicine

The article titled 'MicroRNAs as Therapeutic Targets' was authored by Dr. Michael Czech, Chair of the Program in Molecular Medicine at the University of Massachusetts Medical School, and discussed clinical applications for intervening with microRNAs.

Research by Alnylam and its collaborators at The Rockefeller University has demonstrated that miRNAs can be specifically silenced by using antagomirs, a class of oligonucleotide drugs.

Alnylam believes this approach creates the opportunity to design antagomirs that target miRNAs involved in the cause or pathway of human diseases, such as cancer and viral infection.

"We're thrilled to have the importance of miRNAs and Alnylam's own work in this field recognized and reviewed in one of the world's leading medical journals," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam.

"We believe that the opportunity to target miRNAs involved in human disease with antagomirs is an important extension of our platform to harness the RNAi pathway for discovery of innovative medicines."

Advertisement